Advertisement

Search Results

Advertisement



Your search for ,USE matches 11180 pages

Showing 9751 - 9800


colorectal cancer

Aspirin as Adjuvant Therapy for Colon Cancer: Is the Time Right?

Aspirin has long proved to be a multipotent drug, with efficacy as a pain reliever, anti-inflammatory agent, antiplatelet agent, and cardioprotective agent. In the cancer world, a large literature has accumulated demonstrating its ability to prevent various epithelial malignancies, most notably...

colorectal cancer

Evidence of Recurrence-Free, Disease-Free, and Overall Survival Benefit of Aspirin and COX‑2 Inhibitor Use in Stage III Colon Cancer

In an analysis from the Cancer and Leukemia Group B (CALGB) 89803 adjuvant trial reported in the Journal of the National Cancer Institute, Kimmie Ng, MD, MPH, of Dana-Farber Cancer Institute, Boston, and colleagues found consistent trends suggesting benefit of aspirin use and cyclo-oxygenase-2...

breast cancer
pain management

Opioid-Reduction Strategy for Postoperative Pain After Breast Cancer Surgery

One persistent and potentially debilitating problem breast cancer patients suffer with is postoperative pain. Studies show that proper pain management is an essential component in the healing process, but undertreatment of pain symptoms remains an ongoing issue in the oncology community. Opioids,...

breast cancer

Should We Be Worried If Patients Tolerate Endocrine Therapy Well?

When meeting with patients to discuss adjuvant endocrine therapy for breast cancer, the question often arises, “How will I know that the treatment is working?” While the efficacy of these treatments has been demonstrated for the majority of patients in multiple large randomized clinical trials,...

breast cancer

Analysis Shows No Link Between Aromatase Inhibitor–Related Musculoskeletal/Vasomotor Symptoms and Relapse-Free Survival

Retrospective analyses of the ATAC, TEAM, and BIG 1-98 adjuvant endocrine therapy trials in breast cancer have suggested that treatment-emergent endocrine symptoms may be associated with superior survival outcomes. In a study reported in the Journal of Clinical Oncology, Vered Stearns, MD,...

issues in oncology

20 Years of NCCN: The Best Is Yet to Come

As the National Comprehensive Cancer Network (NCCN) celebrates its 20th year, The ASCO Post asked its Chief Executive Officer, Robert W. Carlson, MD, to reflect on the organization’s accomplishments, mission, and future and on the role he may have played in its success.  The Early Years You became...

global cancer care

How the International Innovation Grant Is Improving Cancer Care for Women in Myanmar

In 2014, the Conquer Cancer Foundation awarded four inaugural International Innovation Grants to aid novel research projects in Colombia, Myanmar, Nigeria, and Tanzania. The program, which supports a 1-year research grant of up to $20,000 to a nonprofit organization or governmental agency in a low- ...

issues in oncology
global cancer care

Noncommunicable Diseases Are the Leading Cause of Death in Low- and Middle-Income Countries

The greatest health threat to people living in low- and middle-income countries is no longer infectious diseases like HIV/AIDS, which has seen a 33% decline in the global rate of new infections since 2001.1 It is the rise of noncommunicable diseases (including cancer, cardiovascular disease, and...

breast cancer
issues in oncology

PRIME II and the Omission of Radiation Therapy in Low-Risk, Elderly Patients Undergoing Breast Conservation: The Time Has Come

Despite the high prevalence of breast cancer worldwide, it is important to recognize that > 40% of all cases occur in women aged 65 years or older in both the United States and the United Kingdom.1,2 Breast cancers in older patients are more often associated with indolent features and with...

breast cancer
issues in oncology

Radiotherapy or Not in Older Women Receiving Breast-Conserving Surgery and Endocrine Treatment?

In the phase III PRIME II trial, designed to assess whether whole-breast irradiation could be omitted in women aged ≥ 65 years with early-stage breast cancer undergoing breast-conserving surgery and receiving adjuvant endocrine treatment, Ian H. Kunkler, MB BChir, FRCR, of Western General Hospital, ...

breast cancer

Mammographic Density After Tamoxifen Initiation Linked to Improved Prognosis for Pre- and Postmenopausal Women With ER-Positive Breast Cancer

An improved prognosis for women with estrogen receptor (ER)-positive breast cancer who experience a large reduction in mammographic density following the initiation of tamoxifen treatment extends to premenopausal as well as postmenopausal women, researchers reported in the Journal of the National...

colorectal cancer

Lower 30-Day Mortality, Increased Likelihood of Adjuvant Chemotherapy With Laparoscopic vs Open Colectomy for Stage III Colon Cancer

“In routine clinical practice, laparoscopic colectomy is associated with a lower 30-day mortality, shorter length of stay, and greater likelihood of adjuvant chemotherapy initiation among stage III colon cancer patients when compared with open colectomy,” according to an analysis of data from the...

integrative oncology
palliative care

Escalation of Oncology Services at End of Life May Be Moderated by Coordinated Care

“Use of oncology-related services is increasingly scrutinized, yet precisely which services are actually rendered to patients, particularly at the end of life, is unknown,” noted an article in the Journal of Oncology Practice. To address this knowledge gap, Eijean Wu, MD, of the Los Angeles County...

colorectal cancer

FDA Approves Ramucirumab for Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) today approved ramucirumab (Cyramza) for use in combination with FOLFIRI (leuco­vorin, fluorouracil, irinotecan) for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab (Avastin)-,...

gynecologic cancers
issues in oncology

Bombarded With Changes in Health Care and Beyond, Gynecologic Oncologists Prepare for the Challenges Ahead

Physicians are being “bombarded” with changes in health care and beyond, Richard R. Barakat, MD, FACS, noted in his Presidential Address at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. These changes are being precipitated by steeply rising health-care costs amid...

supportive care

Researchers Discuss Pilot Study on Hallucinogenic Therapies for Cancer Anxiety

Although varying levels of existential distress are near-ubiquitous among patients with cancer, evidence-based interventions in this clinical area remain somewhat elusive. Seeking to explore novel approaches in the palliative care environment, New York University (NYU) School of Medicine principal...

supportive care

Childhood Cancers: Significant Medical Success but Many Psychosocial Needs Still Unmet

Treatment of childhood cancer is remarkably successful, but still, 2,000 children die of it each year, and for some forms of the disease, no progress has been made at all, said Otis Brawley, MD, Chief Medical Officer, American Cancer Society (ACS). “At least half of all pediatric cancer survivors...

Maintenance of Certification Activities: Earn Points at the ASCO Annual Meeting

The 2015 ASCO Annual Meeting will feature three activities to help attendees earn American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points while onsite. Annual Meeting Practice-Centered Session MOC Self-Assessment Activity This activity is designed for attendees who want ...

Five Reasons to Use Social Media at the ASCO Annual Meeting

Join the discussion: Use #ASCO15 on Twitter to follow and participate in the conversation around the Annual Meeting in real time! During last year’s Annual Meeting, over 43,000 Tweets were sent by more than 8,500 individuals, reaching an estimated 145 million Twitter users. Tweets about the...

issues in oncology

Enhance Your Annual Meeting Experience With Attendee Resources

At the end of May, more than 25,000 oncology professionals from around the world will meet in Chicago for the 2015 ASCO Annual Meeting. This year’s theme, “Illumination & Innovation: Transforming Data into Learning,” reflects the current state of oncology. The accelerating volume and variety of ...

health-care policy
legislation

Maryland Oncologists Faced With Navigating the Maze of Chemotherapy Safety Regulations

In March 2013, 60 Minutes aired a devastating piece about a Massachusetts compounding center that shipped an injectable steroid contaminated with fungus. One of the many ripple effects from this story of horrendous patient suffering was felt in Maryland, where it sparked legislative action in the...

issues in oncology
breast cancer

Informing Decision-Making About Mammography Screening

Overdiagnosis associated with breast cancer screening has been the subject of much attention in recent years. The notion that cancer screening—largely believed to be beneficial—could actually be harmful is simultaneously fascinating and difficult to believe. With the publication of multiple studies ...

breast cancer
issues in oncology

Impact of Informed Decision-Making on Breast Cancer Screening

In a study reported in Lancet, Jolyn Hersch, MApplSc, of the University of Sydney, and colleagues found that use of a decision aid containing information on overdetection in breast cancer screening was associated with an increased rate of informed choice regarding screening, a reduced rate of...

lymphoma

Brentuximab Vedotin After Autologous Stem Cell Transplantation in High-Risk Hodgkin Lymphoma: Implications of the AETHERA Trial

Hodgkin lymphoma is generally thought to be a malignancy with a favorable prognosis. Overall, approximately 80% of patients will have durable, long-term remissions with initial chemotherapy. Some patients, however, demonstrate evidence of disease progression, and these patients usually receive...

breast cancer
gynecologic cancers
kidney cancer
skin cancer
cost of care

NCCN Posters of Interest Included Studies in Kidney, Breast, and Endometrial Cancers, Melanoma, and Cost Issues

The quality and quantity of original research presented at the National Comprehensive Cancer Network (NCCN) Annual Conference continue to grow since poster sessions debuted a few years ago. The ASCO Post offers summaries for just a few that caught our eye, out of more than 65 presented this year....

health-care policy

After Decades of Uncertainty, the Sustainable Growth Rate Formula Is Repealed by Congress

The U.S. Congress recently did something remarkable: both parties reached across the aisle and overwhelmingly passed H.R. 2, a bill that will permanently repeal the sustainable growth rate (SGR), the problematic formula for Medicare reimbursement. It just needed the President’s signature, which it...

breast cancer

Experts Debate: Can We Cure Metastatic Breast Cancer?

Can metastatic breast cancer ever be cured? This issue was debated at the 32nd Annual Miami Breast Cancer Conference by two experts in the field: George W. Sledge, Jr, MD, Professor of Medicine at Stanford University Medical Center, Palo Alto, California, and Clifford A. Hudis, MD, Chief of the...

issues in oncology
health-care policy

ASCO Releases 2015 Report on The State of Cancer Care in America

In March, ASCO published its second annual report, The State of Cancer Care in America: 2015.1 Its findings show a mixed landscape, on the one hand, spotlighting advances in therapy and improving survival rates, but on the other, describing a cancer care system under stress from increasing demand...

cost of care
health-care policy

Creating a Collective Path Forward to Optimize Value in Cancer Care

The Centers for Medicare and Medicaid Services projects that U.S. health-care spending will reach $4.3 trillion and account for 19.3% of the nation’s gross domestic product by 2019.1 Although cancer care represents a small fraction of overall health-care costs, the cost of cancer care is rapidly...

skin cancer

Practice-Changing Study: Pembrolizumab Outperforms Ipilimumab in Advanced Melanoma

Pembrolizumab (Keytruda) proved superior to ipilimumab (Yervoy) for the treatment of unresectable advanced melanoma in the global phase III KEYNOTE-006 trial. Pembrolizumab significantly improved overall survival, progression-free survival, and overall response rate compared with ipilimumab, which...

Profile: Julie M. Vose, MD, MBA, FASCO, Making a Difference in Both Clinical Medicine and Research

At this year’s ASCO Annual Meeting, Julie M. Vose, MD, MBA, FASCO, will begin her term as the Society’s 51st President. It is fitting that the meeting will be held in Chicago, the city where the first seven visionaries met over lunch in 1964 to formulate a medical organization centered on cancer...

p53 Takes Center Stage

BOOKMARKTitle: p53: The Gene That Cracked the Cancer CodeAuthor: Sue ArmstrongPublisher: Bloomsbury PublishingPublication date: November 20, 2014Price: $19.98; hardcover, 288 pages   Completed in April 2003, the Human Genome Project was one of the greatest feats of scientific exploration, an inward ...

hepatobiliary cancer
supportive care

Therapy for Hepatitis C Virus Infection in Patients With Cancer May Prevent Liver Disease Progression

“Hepatitis C virus (HCV) infection is a neglected disease in patients with cancer,” Harrys A. Torres, MD, and colleagues from the University of Texas MD Anderson Cancer Center in Houston noted in the Journal of the National Comprehensive Cancer Network. To rectify that situation, the researchers...

lung cancer

EGFR L858R Mutation in Blood Sample May Serve as Surrogate for Biopsy in Determining EGFR-Mutation Status

Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown that the EGFR L858R...

breast cancer

Emergency Room Visits and Hospitalizations Are Common Among Women With Early Breast Cancer Receiving Chemotherapy

Emergency room visits and hospitalizations are common among patients with early breast cancer receiving chemotherapy, particularly among those receiving a regimen containing docetaxel, according to a study supported by the Ontario Institute of Cancer Research, Toronto. “In this population-based...

Remembering Multiple Myeloma Patient Advocate Michael S. Katz, MBA

I first met Michael Katz, MBA, in 2004, 3 years after my brother, Dom, was diagnosed with multiple myeloma, and we were at a crossroads in his care and needed advice. Although an experimental regimen of thalidomide (Thalomid) and dexamethasone had successfully put Dom in remission for a year (the...

Steps to More Effective Communication

Alan Alda, Co-Founder of the Alan Alda Center for Communicating Science and Visiting Professor at Stony Brook University, suggests these steps to improve scientific communication. The ability to be empathic and imagine what someone else might be thinking or feeling is the key to becoming a more...

Learning to Communicate Science More Effectively

Alan Alda’s passion and appreciation for science extend nearly as far back to his early life as his love of acting. The son of actor Robert Alda, Mr. Alda began his acting career at the age of 16. Although he has appeared in such widely acclaimed films as The Seduction of Joe Tynan, Crimes and...

A Less Is More View of Medicine

BOOKMARKTitle: Less Medicine, More Health: 7 Assumptions That Drive Too Much Medical CareAuthor: H. Gilbert Welch, MDPublisher: Beacon PressPublication date: March 3, 2015Price: $24.95; hardcover, 241 pages He’s the best physician that knows the worthlessness of most medicines. —Benjamin Franklin...

issues in oncology

Building a Better Federal Oncology Workforce

The process of delivering novel treatments for patients with cancer involves a multifaceted and long-term interaction between three distinct entities: clinical researchers, who conduct the trials which test treatments; drug developers, including the pharmaceutical industry, which takes cancer drugs ...

issues in oncology

Taking the Trauma Out of Cancer Care for Children and Adolescents

Getting a cancer diagnosis and going through treatment are difficult for patients of any age, but the experience can be especially traumatizing for the nearly 16,000 infants, children, and adolescents diagnosed each year with cancer,1 especially during the early days of treatment. Young cancer...

colorectal cancer

Cobas KRAS Mutation Test Receives FDA Approval

Roche announced that the U.S. Food and Drug Administration (FDA) has approved the cobas KRAS Mutation Test for diagnostic use. The real-time polymerase chain reaction (PCR) test is designed to identify KRAS mutations in tumor samples from patients with metastatic colorectal cancer and aid...

skin cancer

FDA Accepts Supplemental Biologics License Application for Nivolumab in Patients With Previously Untreated Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has accepted for filing and review Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for nivolumab ­(Opdivo) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority...

colorectal cancer

Ramucirumab With FOLFIRI in Metastatic Colorectal Cancer

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 24, the monoclonal antibody ramucirumab ­(Cyramza) was...

issues in oncology
geriatric oncology

Guidelines for the Treatment of Older Cancer Patients: Task Forces of the International Society of Geriatric Oncology

Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on geriatric oncology. The Task Forces of the International Society of Geriatric Oncology (SIOG) are ...

breast cancer

High Invasive Disease-Free Survival With Adjuvant Paclitaxel and Trastuzumab in Small, Node‑Negative, HER2-Positive Breast Cancers

In a phase II study reported in The New England Journal of Medicine, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that adjuvant paclitaxel and trastuzumab (Herceptin) was associated with high invasive disease-free survival in women with small, node-negative,...

breast cancer

Increased Risk of Secondary Bone Marrow Neoplasia After Adjuvant Breast Cancer Treatment: Risk/Benefit Analysis and Biologic Insights

Ever since the early application of adjuvant chemotherapy for breast cancer decades ago, it has been recognized that there is always a price to pay for its success in reducing breast cancer mortality. Most of that “cost” is commonly considered in terms of the potential morbid short- and long-term...

integrative oncology

Maitake

The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...

ASCO Announces New Class of Participants in Quality Training Program

ASCO has announced the second class of oncology practices for its Quality Training Program. Twelve practices across the United States will participate in this 6-month comprehensive course, which will guide them through quality improvement activities using proven innovative learning techniques....

Taking the Next Step in a Storied Career

On March 31, 2015, Harold Varmus, MD, left his position as Director of the National Cancer Institute (NCI) to join the faculty of Weill Cornell Medical College in New York as its Lewis Thomas University Professor of Medicine. Dr. Varmus was also named Senior Associate Core Member of the New York...

Advertisement

Advertisement




Advertisement